	Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics. Eur Urol Fanti S, Turco F, Tombal B, Walz J, Hofman MS, Hadaschik B, Emmett L, Tilki D, Pecoraro G, Salfi G, Attard G, Beltran H, Bjartell A, Briganti A, Burger IA, Castro E, Cerci JJ, Chiti A, Cooperberg M, Fizazi K, Fossati N, Gafita A, Gallina A, Goffin K, Horvath LG, Hugosson J, Iagaru A, James ND, Kasivisvanathan V, Koh DM, Kristiansen G, Kumar R, Lecouvet F, Loeb S, McKay RR, Morris MJ, Murphy DG, Murthy V, Naoun N, Oprea-Lager DE, Ost P, O'Sullivan J, Padhani AR, Palapattu G, Paone G, Petralia G, Roobol MJ, Sartor OA, Sathekge M, Schuster DM, Seibert TM, Spratt DE, Tempany C, Tunariu N, Vargas HA, Vogl UM, Wyatt AW, Zilli T, Lin HM, Omlin A, Gillessen S, Herrmann K. PMID: 42399196 [PubMed - as supplied by publisher]
	How to focal boost in prostate cancer radiotherapy: ESTRO clinical practice consensus recommendations. Radiother Oncol Willigenburg T, Draulans C, Pos FJ, Seibert TM, Syndikus I, Henry A, Mitchell A, Buijs M, Jereczek-Fossa BA, Spohn SKB, Pommer T, Pieters BR, Tree AC, van der Voort van Zyp JRN. PMID: 42399065 [PubMed - indexed for MEDLINE]
	Integrative Traditional East Asian Medicine-Based Adjunctive Therapies for Patients With Prostate Cancer Undergoing Standard Cancer Treatment: Protocol for a Systematic Review and Meta-Analysis of Randomized Controlled Trials. JMIR Res Protoc Wi SJ, Kim DH, Kim SH, Lee SJ, Park JS, Shin SM, Lee BC, Park SJ. PMID: 42398929 [PubMed - indexed for MEDLINE]
	Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery. Med Oncol Ma J, Qiang Z, Xie W, Jiao L, Mi L, Ma K, Yang Z, Chen G. PMID: 42397660 [PubMed - indexed for MEDLINE]
	Evolving role of biomarkers beyond prostateâ€‘specific antigen in refining prostate cancer screening: From bloodâ€‘based tests to urinary and genetic markers (Review). Mol Med Rep Li L, Zhang L, Li Z, Chai K, Ren W. PMID: 42396659 [PubMed - indexed for MEDLINE]
	Case Report: Kidney preservation using immune checkpoint inhibitors in Muir-TorrÃ© syndrome-associated upper tract urothelial carcinoma, with literature review. Front Immunol Hanna M, Bar-Sela G. PMID: 42396450 [PubMed - indexed for MEDLINE]
	Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. Endocr Oncol Gorman M, Usmani N, Pollak MN, Ghosh S, Elangovan A, Kim J, Thoms J, Bouchard M, Peacock M, Wang Y, Fleshner NE, Campbell H, Vigneault E, Vincent F, So A, Cury FL, Quon HC, Carlson RG Jr, Lambert C, Klotz L, Chi K, Brundage M, Courneya KS, Eigl BJ. PMID: 42395839 [PubMed]
	A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets. bioRxiv Perny A, Jarmale V, Jasti J, Zhong H, Christie A, Miyata J, Nielson A, Kontoyiannis P, Rakheja D, Modrusan Z, Huseni M, Kadel W, Brugarolas J, Kapur P, Rajaram S. PMID: 42395467 [PubMed]
	Optimization of Administered Activity for (64) Cu-SAR-bisPSMA PET Imaging in Primary Prostate Cancer: Results from a Phase I Retrospective Study (PROPELLER Sub-study). World J Nucl Med Lengyelova E, Patel M, Morrish G, Mittra E, Malaroda A, Gervasio O, Armor T. PMID: 42395167 [PubMed]
	LLMs in Problem-Based Learning: The Grounding Issue. Stud Health Technol Inform Sariyar M. PMID: 42394097 [PubMed - indexed for MEDLINE]
	Estimating Mosaic Loss of the Y Chromosome in Male Bladder Cancer Participants Using "All of Us" Data. Stud Health Technol Inform Ye Z, Cui W, Theodorescu D, Finkelstein J. PMID: 42394043 [PubMed - indexed for MEDLINE]
	When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [Â¹â¸F]FDG in high-risk prostate cancer: dual-tracer cohort study. Cancer Imaging Ibrahim EA, Alper E. PMID: 42393801 [PubMed - as supplied by publisher]
	Quality of services and patient reported outcomes for prostate cancer in Tanzania: the role of patients' satisfaction from a cross-sectional study. BMC Urol Nyongole O, Munishi C, Kimu N, Shirima GV, Sangeda RZ, Mseti M, Lugina E, Kiwara F, Sirili N, Chacha F, Nicholaus B, Mruma H, Frumence G, Simba D, Urassa D, Sunguya B. PMID: 42393670 [PubMed - as supplied by publisher]
	Gamma knife radiosurgery for renal cell carcinoma brain metastases across systemic therapy eras: survival, intracranial failure, and lesion-level predictors. J Neurooncol Almeida ND, Sinha S, Fang M, Cheruvu H, Tasgaonkar R, Gulzar B, Madhugiri V, Goulenko V, Prasad D. PMID: 42393321 [PubMed - indexed for MEDLINE]
	Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study. NPJ Precis Oncol Rebuzzi SE, Miskovic V, Fornarini G, Ferri S, Buti S, Piceni M, Signori A, Provenzano L, Banna GL, Rescigno P, Maruzzo M, Bimbatti D, Pollone BR, Basso U, De Giorgi U, Pedrazzoli P, Galli L, Zucali PA, Di Costanzo F, Ghose A, Pedrocchi ALG, Prelaj A. PMID: 42393181 [PubMed - as supplied by publisher]
	Should Male Pattern Baldness Be Considered in Prostate Cancer Risk Assessment? A Systematic Review and Meta-analysis. Eur Urol Focus Larose C, Samhani C, Piché ME, Lachance G, Fradet Y, Robitaille K, Fradet V. PMID: 42392953 [PubMed - as supplied by publisher]
	Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely. Eur Urol Contieri R, van der Heijden AG, Mertens LS. PMID: 42392908 [PubMed - as supplied by publisher]
	Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined (18)F-Flotufolastat PSMA PET and mpMRI. J Nucl Med Hekimsoy T, Sauter AP, Tauber R, Horn T, Jahnen M, Horné F, Petzold JQ, Sasse D, Rauscher I, Eiber M, Weber WA, Erber BM. PMID: 42392697 [PubMed - as supplied by publisher]
	Sensitive detection of prostate cancer antigen 3 (PCA3) in urine based upon CRISPR/Cas12a and gold nanorods (AuNRs). Spectrochim Acta A Mol Biomol Spectrosc Liao W, Li S, Wu S, Yang X, Liu B, Ling L, Zeng Q, Zhang J. PMID: 42391902 [PubMed - as supplied by publisher]
	Assessing the impact of prostate cancer prevention and detection initiatives. Int J Palliat Nurs Narvaez RA, Bongay R, Federez IC, Chan EB, Magno D, Samarita JC, Ferrer M, Peco RA, Sumpay LA, Sangilan NB. PMID: 42391137 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 179729

Page 1 of 8987



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy